These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33555543)

  • 41. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
    Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
    JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma.
    Finon A; Zaragoza J; Maillard H; Beneton N; Bens G; Samimi M; Caille A; Machet L
    Eur J Dermatol; 2018 Feb; 28(1):38-43. PubMed ID: 29336315
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
    Mohapatra P; Prasad CP; Andersson T
    Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum Levels of S100b and NSE Proteins in Patients with Non-Transfusion-Dependent Thalassemia as Biomarkers of Brain Ischemia and Cerebral Vasculopathy.
    Kanavaki A; Spengos K; Moraki M; Delaporta P; Kariyannis C; Papassotiriou I; Kattamis A
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29244749
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
    Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
    Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
    Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
    J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
    Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
    Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.
    Chien AJ; Haydu LE; Biechele TL; Kulikauskas RM; Rizos H; Kefford RF; Scolyer RA; Moon RT; Long GV
    PLoS One; 2014; 9(4):e94748. PubMed ID: 24733413
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision.
    Hartung N; Huynh CT; Gaudy-Marqueste C; Flavian A; Malissen N; Richard-Lallemand MA; Hubert F; Grob JJ
    PLoS One; 2017; 12(5):e0176080. PubMed ID: 28472075
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
    Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
    EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The density and spatial tissue distribution of CD8
    Massi D; Rulli E; Cossa M; Valeri B; Rodolfo M; Merelli B; De Logu F; Nassini R; Del Vecchio M; Di Guardo L; De Penni R; Guida M; Sileni VC; Di Giacomo AM; Tucci M; Occelli M; Portelli F; Vallacchi V; Consoli F; Quaglino P; Queirolo P; Baroni G; Carnevale-Schianca F; Cattaneo L; Minisini A; Palmieri G; Rivoltini L; Mandalà M;
    J Immunother Cancer; 2019 Nov; 7(1):308. PubMed ID: 31730502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation.
    Li YY; Wu C; Shah SS; Chen SM; Wangpaichitr M; Kuo MT; Feun LG; Han X; Suarez M; Prince J; Savaraj N
    Mol Oncol; 2017 Dec; 11(12):1806-1825. PubMed ID: 29094484
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
    Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
    Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients.
    Hauschild A; Michaelsen J; Brenner W; Rudolph P; Gläser R; Henze E; Christophers E
    Melanoma Res; 1999 Apr; 9(2):155-61. PubMed ID: 10380938
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?
    Haueis SA; Kränzlin P; Mangana J; Cheng PF; Urosevic-Maiwald M; Braun RP; Levesque MP; Dummer R; Goldinger SM
    Melanoma Res; 2017 Jun; 27(3):231-237. PubMed ID: 28099366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.